Intravenous versus Intravenous combined with topical administration of tranexamic acid in primary total knee arthroplasty: a randomized controlled trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-14005579

Enrollment

Unknown

Registered

2014-11-29

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage knee joint disease

Interventions

Experimental group:intravenous (15mg/kg) combined with topical (1000mg) use tranexamic acid

Control:Control

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients (18 years and older) undergoing elective unilateral primary TKA for osteoarthritis. All patients were followed up forsix months postoperatively.

Exclusion criteria

Exclusion criteria: both groups included patients undergoing TKA for secondary osteoarthritis (rheumatoid arthritis, posttraumatic arthritis, gouty arthritis), simultaneous bilateral TKA, cardiovascular problems (history of myocardial infarction, atrial fibrillation, angina,heart failure - Class III or IV), cerebrovascular conditions (history of previous stroke or peripheral vascular surgery), clotting disorders or blood dyscrasia, thromboembolic disorders (history of Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE)), preoperative hemoglobin more than 15.0 g/dl, known allergy to TXA, and pregnancy.

Design outcomes

Primary

Measure	Time frame
drainage amount;Invisible blood loss;haemoglobin level;HCT(hematokrit);deep vein thrombosis and pulmonary embolism;	—

Secondary

Measure	Time frame
clincal function evaluation;complications;	—

Contacts

Public ContactYong Jiang

Jiangyong2007@126.com+86 13636704310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026